BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vitiligo readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Vitiligo\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07108283-101@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270326
DTEND;VALUE=DATE:20270327
SUMMARY:zasocitinib: Phase 2 readout est. (NCT07108283)
DESCRIPTION:zasocitinib\, phase 2\, Vitiligo.\nStudy: A Study of Zasocitini
 b in Adults With Nonsegmental Vitiligo\nEstimated primary completion: 26 M
 arch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zasocitini
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 108283
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06163326-5938@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:PF-06651600: Phase 3 readout est. (NCT06163326)
DESCRIPTION:PF-06651600\, phase 3\, Vitiligo.\nStudy: A 52-Week Study to Le
 arn About the Safety and Effects of Ritlecitinib in Participants With Nons
 egmental Vitiligo\nEstimated primary completion: 31 March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pf-06651600#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06163326
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06804811-11030@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ruxolitinib (Opzelura): Phase 3 readout est. (NCT06804811)
DESCRIPTION:Ruxolitinib (Opzelura)\, phase 3\, Vitiligo.\nStudy: A Study to
  Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to <
  12 Years Old) With Nonsegmental Vitiligo\nEstimated primary completion: 3
 0 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolit
 inib-opzelura#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06804811
URL:https://assetmemo.bio/drug/ruxolitinib-opzelura#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06072183-5938@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:PF-06651600: Phase 3 readout est. (NCT06072183)
DESCRIPTION:PF-06651600\, phase 3\, Vitiligo.\nStudy: A 104-Week Study of R
 itlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and
  Stable) Tranquillo 2\nEstimated primary completion: 30 July 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pf-06651600#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06072183
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07625891-62@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Nomelcitinib (D-2570): Phase 2 readout est. (NCT07625891)
DESCRIPTION:Nomelcitinib (D-2570)\, phase 2\, Vitiligo.\nStudy: Study of D-
 2570 in Subjects With Non-Segmental Vitiligo\nEstimated primary completion
 : November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nome
 lcitinib-d-2570#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07625891
URL:https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06118411-12@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06118411)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Vitiligo.\nStudy: A Study To 
 Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Ad
 ult and Adolescent Participants With Vitiligo\nEstimated primary completio
 n: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/upadac
 itinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06118411
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06548360-11030@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280605
DTEND;VALUE=DATE:20280606
SUMMARY:Ruxolitinib (Opzelura): Phase 3 readout est. (NCT06548360)
DESCRIPTION:Ruxolitinib (Opzelura)\, phase 3\, Vitiligo.\nStudy: A Study to
  Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Partic
 ipants With Nonsegmental Vitiligo\nEstimated primary completion: 5 June 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-opzel
 ura#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06548360
URL:https://assetmemo.bio/drug/ruxolitinib-opzelura#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07431177-1372@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280606
DTEND;VALUE=DATE:20280607
SUMMARY:GIA632: Phase 2 readout est. (NCT07431177)
DESCRIPTION:GIA632\, phase 2\, Vitiligo.\nStudy: A Phase IIb Dose-ranging S
 tudy to Assess the Efficacy and Safety of GIA632 in Participants With Non-
 segmental Vitiligo\nEstimated primary completion: 6 June 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/gia632#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07431177
URL:https://assetmemo.bio/drug/gia632#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07595939-11030@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ruxolitinib (Opzelura): Phase 3 readout est. (NCT07595939)
DESCRIPTION:Ruxolitinib (Opzelura)\, phase 3\, Vitiligo.\nStudy: Efficacy a
 nd Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With No
 n-segmental Vitiligo\nEstimated primary completion: 31 December 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-opzelura#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07595939
URL:https://assetmemo.bio/drug/ruxolitinib-opzelura#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07152626-5938@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:PF-06651600: Phase 2 readout est. (NCT07152626)
DESCRIPTION:PF-06651600\, phase 2\, Vitiligo.\nStudy: Combination Approach 
 With Ritlecitinib and nbUVB Compared to Ritlecitinib Alone for Treating Vi
 tiligo\nEstimated primary completion: 1 January 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pf-06651600#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07152626
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07896434-12@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20320831
DTEND;VALUE=DATE:20320901
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT07896434)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Vitiligo.\nStudy: A Study to 
 Learn How Effective\, Safe\, and Tolerable Upadacitinib is for Young Parti
 cipants With Non-segmental Vitiligo\nEstimated primary completion: August 
 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/upadacitinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078964
 34
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
